Finlay Institute

CPLAY is a novel serious-game platform combining miniaturized, instrumented building bricks with a tablet interface and AI-driven activity recognition to deliver personalized, gamified upper-limb rehabilitation for children with Developmental Coordination Disorder or Cerebral Palsy. Developed through a co-design process with therapists, engineers, parents and children, two IMU-equipped brick form factors transmit 70 Hz motion data via Bluetooth to a tablet hosting fifteen progressively challenging 3D assembly tasks enriched with rewards and audiovisual feedback. In a clinical feasibility trial, 30 children (mean age 9.1 ± 1.0 years) performed each model twice under supervision; synchronized motion and video data were annotated to train signal-processing routines and deep-learning classifiers. Signal processing detected all 36 movement and fall events (one false positive), while the Transformer model outperformed other approaches, achieving 86.0% multi-class accuracy and 85–96% binary accuracy across activity labels. These results demonstrate CPLAY's ability to objectively detect and classify key rehabilitation movements, paving the way for adaptive, AI-driven therapy, with future work focused on embedding a recommendation engine, scaling trials and refining AI models. • A co-design approach ensuring holistic development of a novel rehabilitation tool. • Gamification boosts engagement, attention, and motivation during therapy sessions. • Data from instrumented bricks trains AI to detect rehabilitation events in real time. • Collects cognitive and motor data to enable personalized rehabilitation plans.

Background: Dermatophytosis are the leading cause of fungal infections worldwide. Objective: To compare the efficacy and safety of ozonated sunflower oil versus ketoconazole and terbinafine in patients with dermatophytosis. Methods: Multicenter Phase III study, it had an open, randomized, comparative design, with three parallel group to which ozonated sunflower oil was apply, or ketoconazole, or terbinafine, twice a day for 6 weeks. The effect on the clinical and mycological cure rate was prefix as the primary efficacy variable. The effect on treatment time to achieve cure was consider as a secondary efficacy variable. All data were analyzed by the intention-to-treat method. Results: The study included 300 patients of both sexes with a diagnosis of dermatophytosis, who were randomly distributed into three groups that received ozonated sunflower oil, or ketoconazole, or terbinafine, respectively. Treatment with ozonated sunflower oil produced a total clinical and mycological cure rate in 78% of patients, similar to ketoconazole (78%) and terbinafine (77%) treatment. Complete mycological cure was achieved in 87% of patients treated with ozonated sunflower oil, similar to ketoconazole (88%) and terbinafine (89%) treatments. Regarding the healing time, of the 233 patients with complete clinical cure, 10 patients (4.3%) were completely cure after 2 weeks of treatment, 58 patients (24.9%) after 4 weeks and 164 patients (70.4%) after 6 weeks. The treatments were safe and well tolerated.

There are several operative modes to address hand fractures to gain better anatomical and functional results including external fixator, percutaneous K-wire fixation, lag screw fixation, tension band wiring, intra-medullary nails or wires, and plate-screw fixation. We evaluated the results of plate osteosynthesis in fractures of metacarpals and phalanges in a prospective manner. A total 50 adults (19-60 years) of either sex having 58 fractures managed by miniature plate osteosynthesis and followed for a minimum six months (6-19), including metacarpal and phalangeal fractures (unstable or serial fractures), intra-articular fractures, fracture-dislocation of proximal interphalangeal and distal interphalangeal joints with joint incongruity or subluxation were enrolled while contaminated compound fractures, pathological fractures and cases of reimplantation were excluded from study. Clinical assessment was done using the American Society for Surgery of the Hand (ASSH), total active flexion (TAF), total active range of motion (TAM) score, and the Disabilities of the Arm, Shoulder, and Hand (quick DASH) score while sequential radiographs were done at each follow-up. All the fractures had perfect union clinically as well as radiologically with a mean duration of six weeks while functional outcomes in reference to clinical scores were observed excellent and fair in all cases. None of the cases had any loss of reduction, loosening of the implant, or other major complications. Miniature plate fixation provides enough stability in metacarpal and phalanges fractures, thereby allowing immediate active movements, which leads to excellent functional outcomes and early return to normal activities.

The protein-based SARS-CoV-2 vaccines FINLAY-FR-2 (Soberana 02) and FINLAY-FR-1A (Soberana Plus) showed good safety and immunogenicity in phase 1 and 2 trials, but the clinical efficacy of the vaccine remains unknown. To evaluate the efficacy and safety of a 2-dose regimen of FINLAY-FR-2 (cohort 1) and a 3-dose regimen of FINLAY-FR-2 with FINLAY-FR-1A (cohort 2) in Iranian adults. A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial was conducted at 6 cities in cohort 1 and 2 cities in cohort 2. Participants included individuals aged 18 to 80 years without uncontrolled comorbidities, coagulation disorders, pregnancy or breastfeeding, recent immunoglobulin or immunosuppressive therapy, and clinical presentation or laboratory-confirmed COVID-19 on enrollment. The study was conducted from April 26 to September 25, 2021. In cohort 1, 2 doses of FINLAY-FR-2 (n = 13 857) or placebo (n = 3462) were administered 28 days apart. In cohort 2, 2 doses of FINLAY-FR-2 plus 1 dose of FINLAY-FR-1A (n = 4340) or 3 placebo doses (n = 1081) were administered 28 days apart. Vaccinations were administered via intramuscular injection. The primary outcome was polymerase chain reaction-confirmed symptomatic COVID-19 infection at least 14 days after vaccination completion. Other outcomes were adverse events and severe COVID-19. Intention-to-treat analysis was performed. In cohort 1 a total 17 319 individuals received 2 doses and in cohort 2 5521 received 3 doses of the vaccine or placebo. Cohort 1 comprised 60.1% men in the vaccine group and 59.1% men in the placebo group; cohort 2 included 59.8% men in the vaccine group and 59.9% in the placebo group. The mean (SD) age was 39.3 (11.9) years in cohort 1 and 39.7 (12.0) years in cohort 2, with no significant difference between the vaccine and placebo groups. The median follow-up time in cohort 1 was 100 (IQR, 96-106) days and, in cohort 2, 142 (137-148) days. In cohort 1, 461 (3.2%) cases of COVID-19 occurred in the vaccine group and 221 (6.1%) in the placebo group (vaccine efficacy: 49.7%; 95% CI, 40.8%-57.3%) vs 75 (1.6%) and 51 (4.3%) in cohort 2 (vaccine efficacy: 64.9%; 95% CI, 49.7%-59.5%). The incidence of serious adverse events was lower than 0.1%, with no vaccine-related deaths. In this multicenter, randomized, double-blind, placebo-controlled, phase 3 trial of the efficacy and safety of FINLAY-FR-2 and FINLAY-FR-1A, 2 doses of FINLAY-FR-2 plus the third dose of FINLAY-FR-1A showed acceptable vaccine efficacy against symptomatic COVID-19 as well as COVID-19-related severe infections. Vaccination was generally safe and well tolerated. Therefore, Soberana may have utility as an option for mass vaccination of the population, especially in resource-limited settings, because of its storage condition and affordable price. isrctn.org Identifier: IRCT20210303050558N1.

The present investigation seeks to know how the image of such a prestigious institution increases when executing corporate social responsibility actions, since today institutions seek to develop in an integral way, complying with adequate criteria to contribute to society. For this, the general objective was considered to determine the relationship of corporate social responsibility in the image of the brand at the Antenor Orrego Private University, 2022, for which a correlational type of investigation was used, with a non-experimental design, considering a finite population. of 26,086 students, and applying the formula of finite populations, a sample of 371 students from the Antenor Orrego Private University was determined, for which the technique was applied to the survey, with the questionnaire instrument, which was validated by 3 expert teachers and reached a Cronbach's alpha reliability level of 0.97. Obtaining for results aSpearman's Rho of 0.767 and a significance level of Sig.<0.01, so the alternate hypothesis could be accepted and the null hypothesis rejected.Likewise, it was obtained as a result that the level of corporate social responsibility is high with an indicator of 66.3%.Therefore, it is concluded that there is a direct and significant relationship between corporate social responsibility and the image of the brand at the Antenor Orrego Private University.

&lt;p&gt;Caracterizar la ense&ntilde;anza en estudiantes de la carrera de medicina a trav&eacute;s de las aulas especializadas en Medicina de Desastres, es el objetivo de la presente investigaci&oacute;n, La poblaci&oacute;n est&aacute; constituida por los dos Grupos B&aacute;sicos de Trabajo (GBT) que est&aacute; compuesta por 69 (100%) de estudiantes que cursan el quinto a&ntilde;o de la carrera de medicina del Hospital Docente Cl&iacute;nico Quir&uacute;rgico Dr. Octavio de la Concepci&oacute;n y de la Pedraja que fueron escogidos hace tres cursos desde el 2017-2018; 2018-2019; 2019- 2020. A estos estudiantes se les aplic&oacute; un pre prueba pedag&oacute;gica, lo cual el GBT I (34) es el grupo experimental y GBT 2 (35) es el grupo de control. Lo cual arrojo como resultado que los estudiantes que recibieron los contenidos en las aulas especializadas tienen mejores resultados acad&eacute;micos referidos a la calidad de las notas.&lt;/p&gt;

Com o Código de Processo Civil de 2015, o atentado deixou de ser tratado como procedimento cautelar. A opção legislativa prestigia respeito ao diálogo processual participativo e atribui ao instituto o caráter expresso de dever processual de conteúdo negativo. Contudo, com o fim das cautelares típicas, perdeu-se meio processual para denúncia do atentado e lócus específico para sua análise. Urge pensar em formas de sistematizar meios processuais para tratamento do tema. O princípio do aproveitamento de meios pode apontar caminhos para cuidar da questão.

Abstract BackgroundThe Receptor Binding Domain (RBD) of the SARS-CoV-2 spike protein is the target for many COVID-19 vaccines. Here we report results for phase 1 clinical trial of two COVID-19 vaccine candidates based on recombinant dimeric RBD (d-RBD).MethodsWe performed a randomized, double-blind, phase I clinical trial in the National Centre of Toxicology in Havana. Sixty Cuban volunteers aged 19-59 years were randomized into three groups (20 subjects each): 1) FINLAY-FR-1 (50 mcg d-RBD plus outer membrane vesicles from N. meningitidis); 2) FINLAY-FR-1A-50 mcg d-RBD (three doses); 3) FINLAY-FR-1A-25 mcg d-RDB (three doses). The FINLAY-FR-1 group was randomly divided to receive a third dose of the same vaccine candidate (homologous schedule) or of FINLAY-FR-1A-50 (heterologous schedule). The primary outcomes were safety and reactogenicity. The secondary outcome was vaccine immunogenicity. Humoral response at baseline and following each vaccination was evaluated using live-virus neutralization test, anti-RBD IgG ELISA and in-vitro neutralization test of RBD:hACE2 interaction.ResultsMost adverse events were of mild intensity (63.5%), solicited (58.8%), and local (61.8%); 69.4% with causal association with vaccination. Serious adverse events were not found. The FINLAY-FR-1 group reported more adverse events than the other two groups. After the third dose, anti-RBD seroconversion was 100%, 94.4% and 90% for the FINLAY-FR-1, FINLAY-FR-1A-50 and FINLAY-FR-1A-25 respectively. The in-vitro inhibition of RBD:hACE2 interaction increased after the second dose in all formulations. The geometric mean neutralizing titres after the third dose rose significantly in the group vaccinated with FINLAY-FR-1 with respect to the other formulations and the COVID-19 Convalescent Serum Panel. No differences were found between FINLAY-FR-1 homologous or heterologous schedules.ConclusionsVaccine candidates were safe and immunogenic, and induced live-virus neutralizing antibodies against SARS-CoV-2. The highest values were obtained when outer membrane vesicles were used as adjuvant.Trial registryhttps://rpcec.sld.cu/en/trials/RPCEC00000338-En